Clinically, tamoxifen (Tam), a selective estrogen receptor (ER) antagonist, is widely used as an adjuvant therapy in ER+ breast cancer treatment, but many breast cancer patients treated with Tam eventually develop drug resistance. This evidence concerns the gene ESR1 and breast carcinoma.